Premier Research appoints Anthony Orlando and Bruce C. Stouch to New Senior Management Positions
Premier Research Group plc (AIM: PRG) ("Premier ResearchÅh, ÅgCompany" or ÅgGroupÅh), the international pharmaceutical services group today announces the appointment of Anthony Orlando, Ph.D. and Bruce C. Stouch, Ph.D. to senior management positions in Premier Research.
PHILADELPHIA, May 10 -- Premier Research Group plc (AIM: PRG) ("Premier Research," "Company" or "Group), the international pharmaceutical services group today announces the appointment of -- Anthony Orlando, Ph.D. and Bruce C. Stouch, Ph.D. to senior management positions in Premier Research.
Dr Anthony Orlando, Ph.D. has joined the US Operations of Premier Research Group plc in the new position of Executive Director, Data Operations. Dr. Orlando brings an exceptional background in Biostatistics and Data Management over the past thirty years including key roles in pharmaceutical companies, the National Center for Toxicological Research/FDA and at major contract research organizations. He most recently joined the company from his position as Vice President, Biostatistics at SFBC New Drug Services. Dr. Orlando holds a Ph.D. in Biometry from Yale University has co-authored many papers in his area of expertise and has supported several drug NDAs for a variety of indications. He will be responsible for US data management, programming and biostatistics for Premier Research.
In addition to Dr. Orlandofs position, Premier Research also is pleased to announce that Bruce C. Stouch, Ph.D. has taken the international position of Chief Scientific Officer for the company. In Dr. Stouchfs new role, he will lead the company's efforts supporting expert FDA/statistical clinical design and analysis capabilities. He will also establish and expand the companyfs new initiative into Bayesian monitoring and analysis methods. Dr. Stouch has over 15 years of biostatistics experience in pharmaceuticals.
For 12 years, Dr. Stouch held the position of Director of Biostatistics and Scientific Data Management at Johnson & Johnson in Exton, PA, where he was responsible for strategic development and implementation of pharmacoeconomic models of emerging technologies in several therapeutic areas. Dr. Stouch has been involved in over two dozen publications and acknowledgements. He holds an academic appointment at the Philadelphia College of Medicine as Director, Biostatistics and Clinical Epidemiology. Dr. Stouch received his Ph.D. in Biostatistics and Epidemiology from Jefferson Medical College in 1997 through a program sponsored by Johnson & Johnson, and trained in post-graduate studies from Temple University, Jefferson Medical College, and Harvard School of Public Health.
Dr Simon Yaxley, CEO of Premier Research Group plc, commented: gWe are proud and pleased to announce the significant strengthening of our data management and statistics capabilities in the US Operations. We also believe that Tony and Bruce place our company at the forefront of trial design, monitoring and analysis methods worldwide.
About Premier Research
Premier Research Group plc is a contract research organisation focused on the design, management and reporting of all phases of clinical trials on behalf of pharmaceutical and biotechnology companies. The Company specialises in oncology, central nervous system, paediatrics and anti-infectives.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
